Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:30:33.091Z.
Calculation as of: 2026-10-06T13:30:33.091Z.
Quote observation: 2026-10-06T13:30:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8bc85e2d5351a47333dd9131f39a7cf6b6d5f02586c5202dd123a5ad4370615
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$111.17M
EV/EBITDA Ratio
N/A
TTM Avg
20.17x
3Y Avg
20.17x
5Y Avg
20.17x
Market Cap
$108.94M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.58M
EV/EBITDA Ratio
N/A
TTM Avg
20.46x
3Y Avg
22.62x
5Y Avg
53.44x
Market Cap
$115.55M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apyx Medical Corporation (APYX) | $110.75M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A | 20.17x | 20.17x | 20.17x |
| Immunic, Inc. (IMUX)vs › | $110.74M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.94M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $112.56M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.58M | N/A | 20.46x | 22.62x | 53.44x |
| Coya Therapeutics, Inc. (COYA)vs › | $114.00M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.55M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $115.69M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
